In this case, the motor/encoder cables may have output errors: check the connection of the cables. Deviation overflow may occur before fixing of the electric angle (at Z-phase non-detection). Also, this error occurs when you try to execute a point through I/O that does not exist.ĬAUSE: The position deviation counter overflowed.ĪCTION: Check if loads interfere with peripheral objects, the brake is released, and other load conditions. When release is not possible with the controller power supplied, you will need to either execute a common parameter edit or initialize the controller.
Crows zero 3 subtitle serial#
Provide setting so that either of the functions is effective.ĬAUSE: Incorrect data being sent via serial or fieldbus.ĪCTION: Check the values sent make sure it is within range.Įxecute a common parameter edit or initialize the controller. (Example) This error occurs when the magnitude relationship of a pair of range parameters is inappropriate, such as when the value of soft limit- is mistakenly set to 300 mm, when the value of soft limit+ is 200.3 mm.ĪCTION: Change the parameters to appropriate values.ĬAUSE: Move command input when no target position data was set in the "Position" field.Ĭ: The target position in the "Position" field exceeds a soft limit setting.Ī: Change the target position to a value inside the soft limit setting.Ĭ: An incremental target position was specified in the "Position" field in the 3-point type controller.Ī: Specify an absolute target position (expand the position table view to see this column).Ĭ: Pressing operation was specified while the vibration suppress control function remained effective.Ī: The vibration suppress control function and pressing operation cannot be used concurrently. ErrorĬAUSE: The input range of parameter range data is not appropriate. For In Vitro Diagnostic UseĬontact an Illumina representative for regional availability.E-Con: includes E-Con, ROBO Cylinder RCP2, RCP, RCS, ERC, ERC2, SCON, PCON, ACON Controllers. The Illumina COVIDSeq Test is only for use under the Food and Drug Administration’s Emergency Use Authorization. The Illumina COVIDSeq Test is intended for use by qualified and trained clinical laboratory personnel specifically trained in the use of the NovaSeq 6000 Sequencing System, the NextSeq 2000 Sequencing System, the NextSeq 500 Sequencing System, the NextSeq 550 Sequencing System, or the NextSeq 550Dx Instrument, as well as Next-Generation Sequencing workflows and in vitro diagnostic procedures.
Negative results must be combined with clinical observations, patient history, and epidemiological information. Laboratories within the United States and its territories are required to report all positive results to the appropriate health authorities.Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Positive results do not rule out bacterial infection or co-infection with other viruses. Positive results are indicative of the presence of SARS-CoV-2 RNA clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. The SARS-CoV-2 RNA is generally detectable in respiratory specimens during the acute phase of infection. Results are for the identification of SARS-CoV-2 RNA. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C.
The Illumina COVIDSeq Test is a Next-Generation Sequencing (NGS) in vitro diagnostic test on the Illumina NovaSeq 6000 Sequencing System, NextSeq 2000 Sequencing System, NextSeq 500 Sequencing System, NextSeq 550 Sequencing System, or NextSeq 550Dx Instrument intended for the qualitative detection of SARS-CoV-2 RNA from nasopharyngeal (NP) swabs, oropharyngeal (OP) swabs, anterior nasal swabs, mid-turbinate nasal swabs, nasopharyngeal wash/aspirates, nasal aspirates, and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19 by their healthcare provider.
0 kommentar(er)
